- Home
- RDHL vs PPCB Comparison
RDHL vs PPCB Comparison
Compare RDHL & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDHL | PPCB |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | Israel | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 5.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RDHL | PPCB |
|---|---|---|
| Price | $1.36 | $0.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 108.4K |
| Earning Date | 09-05-2025 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,550,000.00 | N/A |
| Revenue This Year | $381.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 157.62 | N/A |
| 52 Week Low | $0.91 | $0.30 |
| 52 Week High | $6.80 | $145.46 |
Technical Indicators
Market Signals| Indicator | RDHL | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | N/A |
| Support Level | $1.20 | N/A |
| Resistance Level | $1.38 | N/A |
| Average True Range (ATR) | 0.11 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 82.54 | 0.00 |
Price Performance
Historical ComparisonAbout RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.